GlaxoSmithKline starts human testing of two bird-flu vaccines

Article Abstract:

Vaccines are being developed for the H5N1 strain of avian influenza by GlaxoSmithKline PLC of the United Kingdom. Human testing has begun on two potential vaccines and it is hoped to have a vaccine in production by the beginning of 2007. 105 people have been killed by the virus in the past two years and health officials are worried about a possible pandemic.

---

Glaxo announces breakthroug on bird-flu vaccine; net rises

Article Abstract:

GlaxoSmithKline PLC of the United Kingdom has perfected an avian influenza vaccine that will be ready for market by the end of 2006. The pharmaceutical company posted a 14 percent net profit increase for the second quarter to 1.32 billion Pounds ($2.43 billion) from 1.16 billion Pounds last year.

Vaccines, Company overview

---

Similar abstracts:

• Abstracts: Glaxo aims to boost prospects of four promising cancer drugs. Britain stirs outcry by weighing benefits of drugs versus price
• Abstracts: Lea and Perrins Cook's Helper Cooking Sauce - new country. Stovit Fruta Jam. Provitus Chrzan Z Zurawinowy
• Abstracts: Ford plans more cutbacks at Jaguar. Struggling Ford looks to get a lift - from slumping Volvo's new models. Steering clear: auto outsider gets Fiat going by flouting industry traditions; Marchionne keeps all plants open, cuts discounting, sells technology to rivals; taking an ax to management
• Abstracts: Delphi delays bid to void Union pacts. Ford posts $1.19 billion loss as revenue drops nine percent. Ford posts net loss of $123 million
• Abstracts: SkyePharma attracts interest. AstraZeneca is on prowl outside its own lab walls. Big drug makers take a pass on Serono

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.